A variability in response of osteoclasts to zoledronic acid is mediated by smoking-associated modification in the DNA methylome

Clinical trials have shown zoledronic acid as a potent bisphosphonate in preventing bone loss, but with varying potency between patients. Human osteoclasts ex vivo reportedly displayed a variable sensitivity t...

Source: Clinical Epigenetics - March 13, 2023 Category: Research Authors: Qihua Tan, Ana ïs Marie Julie Møller, Chuan Qiu, Jonna Skov Madsen, Hui Shen, Troels Bechmann, Jean-Marie Delaisse, Bjarne Winther Kristensen, Hong-Wen Deng, David Karasik and Kent Søe Tags: Research Source Type: research